7 月 8 日,CDE 官网显示,荣昌生物维迪西妥单抗新适应症申报上市,用于联合特瑞普利单抗治疗 HER2 表达的局部晚期或转移性尿路上皮癌患者,HER2 表达定义为 HER2 免疫组织化学检查结果为 1+、2+ 或 3+。这是该产品申报上市的第 5 项适应症。*如需获取 2025 年更多新药报上市情报,扫描文末二维码添加小音,即可免费下载。来源:CDE 官网维迪西妥单抗是荣昌生物开发的 HER2...
Source Link7 月 8 日,CDE 官网显示,荣昌生物维迪西妥单抗新适应症申报上市,用于联合特瑞普利单抗治疗 HER2 表达的局部晚期或转移性尿路上皮癌患者,HER2 表达定义为 HER2 免疫组织化学检查结果为 1+、2+ 或 3+。这是该产品申报上市的第 5 项适应症。*如需获取 2025 年更多新药报上市情报,扫描文末二维码添加小音,即可免费下载。来源:CDE 官网维迪西妥单抗是荣昌生物开发的 HER2...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.